-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Hexo Stock Still Has a Major Cash Problem
Don't bother buying Hexo stock here. Instead, look for stronger cannabis stocks that have better balance sheets and bigger potential.
How Canopy Growth Stock Looks After Fourth-Quarter Earnings
Canopy Growth recently reported earnings, so let's take a look at how the cannabis company and CGC stock look after the release.
Buy Canopy Growth Stock as Cannabis Again Enters the Spotlight
Canopy Growth stock has been trading better lately, giving investors a glimpse of what CGC stock can do if it regains momentum.
Canopy Growth Has a Catalyst That Few Are Talking About
The devastation from the coronavirus spared very few sectors and marijuana wasn’t one of them. However, this has created a long-term catalyst for CGC stock that few are talking about.
Don’t Judge Pfizer by Its Vaccine Efforts
Pfizer hopes its cash and production infrastructure can quickly replace revenue lost in the spin-out of its generics and consumer businesses.
NowRX Puts Pharmacists in a Warehouse and Employees Making the Delivery
Right now NowRX is only operating in California, where it has delivered 150,000 prescriptions to 18,000 customers. But it has nationwide ambitions.
Catalysts Remain in Play, but Canopy Growth Stock Remains a Hold for Now
Potential needle-movers remain in motion for CGC stock. But as shares may not reflect continued challenges, hold off buying for now.
Only a Miracle Can Save Tilray Stock Now
TLRY stock is down over 97% in under two years, and there's no stopping the free fall as the company struggles on multiple fronts.
Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk
Analysts call ABBV stock a bargain after its $63 billion purchase of Allergan, whose existing drugs and pipeline are now expected to replace revenue from Humira.
Approach Volatile Cannabis Producer Tilray Stock With Caution
Tilray has promise but near-term volatility should make investors cautious about TLRY stock.
The Amazon of Pharmacy: NowRx Could Be a Big Winner
Pharmacy start-up NowRx is in the very early stages of disrupting the $400 billion legacy pharmacy market.
Buy the Post-Earnings Dip in Canopy Growth Stock Now
Canopy Growth's fourth-quarter earnings report was not good. But the big-picture trends remain favorable, and CGC stock will bounce back.
Canopy Growth Stock Is Still Among the Most Compelling Marijuana Plays
CGC stock is well-positioned to become a leader in the cannabis industry with its steady partnership with a beverage industry giant.
Tilray Stock Is a Loser in the Cannabis World
Compared to its innovative peers like Cronos and Canopy Growth, Tilray is destined to fail. That's why investors should avoid TLRY stock now.
Constellation Brands Must Exercise Warrants to Keep Canopy Growth Alive
Canadian Canopy Growth is burning through cash way too quickly. That's why CGC stock is relying on Constellation Brands for survival.
AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions
With AbbVie's buyout of Allergan officially finalized, ABBV stock has moved significantly higher since then. However, ABBV is so much more than this headline event.
